Institute of Genomics and Integrative Biology (IGIB), constituent lab of CSIR, has signed a MoU with TATA Sons for licensing of KNOWHOW for FELUDA in order to execute rapid diagnosis of COVID-19. The MoU aims to provide license which will enable transfer of the knowledge for scaling up the KNOWHOW in the form of a kit in order to employ it for COVID-19 testing on ground as soon as possible. Hence, as per MoU, CSIR-IGIB will now work along with TATA Sons to bring FELUDA for widespread use at the earliest.
Click Here To Get Test Series For SBI PO 2020
FNCAS9 Editor Linked Uniform Detection Assay (FELUDA) has been designed to alleviate the current COVID-19 situation and cater to mass testing. The main advantages of FELUDA is its affordability, relative ease of use as well as non-dependency on expensive Q-PCR machines.
NBFCs or Non-Banking Financial Companies, are becoming popular around the world. They help people by…
Many countries in the world are known for different qualities like power, beauty or culture.…
Many actors around the world have earned huge wealth through films, TV shows and business…
Indian middle-order batter Shreyas Iyer has been awarded the ICC Men’s Player of the Month…
The wholesale price inflation (WPI) in India saw a decline to 2.05% in March 2025,…
On April 14, 2025, the Office of the Principal Scientific Adviser (PSA) to the Government…